The mixed analyst ratings for CRISPR Therapeutics indicate that there is no clear consensus on the stock's short-term direction. The average 12-month price target of $65.59, which has increased by 4.94% over the past month, suggests that analysts are generally positive about the stock's future performance. However, the range of ratings and the fact that the average price target has only increased by a moderate amount indicate that the stock's short-term price movement is uncertain.